Ptc Therapeutics, INC.
Brands
This company sells these brands.
- treatments
- AADC deficiency
- Duchenne muscular dystrophy
- Friedreich's ataxia
- splicing
- inflammation/ferroptosis
- caregivers
- healthcare providers
- investors
Open positions
Openings read from Ptc Therapeutics, INC.’s own job board on Workday, last checked OCT 28, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Regional DirectorDubai Science Park; Saudi Arabia, Riyadh · posted OCT 28, 2026
- Marketing & Communications ManagerTokyo · posted OCT 23, 2026
- Senior Manager, Statistical ProgrammingUSA - New Jersey - Warren; Remote(US-Pennsylvania); Remote(US-New York) · posted OCT 23, 2026
- Senior Manager, Global Clinical Regulatory LeadUSA - New Jersey - Warren · posted OCT 23, 2026
- Associate Director, Clinical OperationsUSA - New Jersey - Warren; Remote(US-Connecticut); Remote(US-Maryland); Remote(US-Washington, DC); Remote(US-New York); Remote(US-Pennsylvania); Remote(US-Massachusetts); Remote(US-Delaware) · posted OCT 22, 2026
- Senior Manager, Clinical OperationsUSA - New Jersey - Warren; Remote(US-Connecticut); Remote(US-Maryland); Remote(US-Washington, DC); Remote(US-New York); Remote(US-Pennsylvania); Remote(US-Massachusetts); Remote(US-Delaware) · posted OCT 22, 2026
- Senior Manager, Clinical OperationsUSA - New Jersey - Warren; Remote(US-Connecticut); Remote(US-Washington, DC); Remote(US-Maryland); USA - New York - New York (Remote); Remote(US-Pennsylvania); Remote(US-Massachusetts); Remote(US-Delaware) · posted OCT 21, 2026
- Patient Support Specialist - Bilingual (West Coast Candidates)Remote (United States); Remote(US-California); Remote(US-Nevada) · posted OCT 21, 2026
- Key Account Manager JapanJapan (Remote) · posted OCT 21, 2026
- Senior Manager, BiostatisticsUSA - New Jersey - Warren · posted OCT 20, 2026
33 more on the company’s board
Supplier designations
Self-certified by the company in its SAM.gov registration
Patents
174 US patents granted 2002–2025, 47 of them in the five years to SEP 2025.
- Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomiaUS 12,398,140 · granted AUG 26, 2025
- Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomiaUS 12,384,797 · granted AUG 12, 2025
- Compounds for treating Huntington's diseaseUS 12,384,789 · granted AUG 12, 2025
- 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereofUS 12,281,083 · granted APR 22, 2025
- Heteroaryl compounds for treating Huntington's diseaseUS 12,139,499 · granted NOV 12, 2024
Newest 5 shown · Granted to Ptc Therapeutics, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Ptc Therapeutics, INC. | Warren | NJ | 500+ | ACTIVE |
WARN Act notices
- WARN notice effective DEC 27, 2023 · 308 employees · Plainfield, NJ
- WARN notice effective AUG 21, 2023 · 94 employees · Plainfield, NJ
Filed with the state under the federal WARN Act · WARN Act notices feed, CC BY 4.0
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.